Clinical Trial Update: Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tisagenlecleucel against blinatumomab or inotuzumab for relapsed/refractory B-cell precursor ALL has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• tisagenlecleucel (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia | Phase 3 | Status: WITHDRAWN